Download Disease-Modifying Targets in Neurodegenerative Disorders Ebook PDF

Disease-Modifying Targets in Neurodegenerative Disorders

Disease-Modifying Targets in Neurodegenerative Disorders
Paving the Way for Disease-Modifying Therapies

by Veerle Baekelandt,Evy Lobbestael

  • Publisher : Academic Press
  • Release : 2017-03-31
  • Pages : 320
  • ISBN : 012805266X
  • Language : En, Es, Fr & De
GET BOOK

Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies examines specific neurodegenerative disorders in comprehensive chapters written by experts in the respective fields. Each chapter contains a summary of the disease management field, subsequently elaborating on the molecular mechanisms and promising new targets for disease-modifying therapies. This overview is ideal for neuroscientists, biomedical researchers, medical doctors, and caregivers, not only providing readers with a summary of the way patients are treated today, but also offering a glance at the future of neurodegenerative disorder treatment. Provides a comprehensive overview of how key proteins in neurodegenerative disorders can be used as targets to modify disease progress Summarizes how patients are treated today, providing a glance at future disease management Includes intelligible and informative information that is perfect for non-specialists, medical practitioners, and scientists Written and peer reviewed by outstanding scientists in their respective fields

Biometals in Neurodegenerative Diseases

Biometals in Neurodegenerative Diseases
Mechanisms and Therapeutics

by Anthony R. White,Michael Aschner,Lucio G. Costa,Ashley I. Bush

  • Publisher : Academic Press
  • Release : 2017-04-28
  • Pages : 462
  • ISBN : 0128045639
  • Language : En, Es, Fr & De
GET BOOK

Biometals in Neurodegenerative Diseases: Mechanisms and Therapeutics is an authoritative and timely resource bringing together the major findings in the field for ease of access to those working in the field or with an interest in metals and their role in brain function, disease, and as therapeutic targets. Chapters cover metals in Alzheimer’s Disease, Parkinson’s Disease, Motor Neuron Disease, Autism and lysosomal storage disorders. This book is written for academic researchers, clinicians and advanced graduate students studying or treating patients in neurodegeneration, neurochemistry, neurology and neurotoxicology. The scientific literature in this field is advancing rapidly, with approximately 300 publications per year adding to our knowledge of how biometals contribute to neurodegenerative diseases. Despite this rapid increase in our understanding of biometals in brain disease, the fields of biomedicine and neuroscience have often overlooked this information. The need to bring the research on biometals in neurodegeneration to the forefront of biomedical research is essential in order to understand neurodegenerative disease processes and develop effective therapeutics. Authoritative and timely resource bringing together the major findings in the field for those with an interest in metals and their role in the brain function, disease, and as therapeutic targets Written for academic researchers, clinicians and advanced graduate students studying, or treating, patients in neurodegeneration, neurochemistry, neurology and neurotoxicology Edited by international leaders in the field who have contributed greatly to the study of metals in neurodegenerative diseases

Molecular Targets in Protein Misfolding and Neurodegenerative Disease

Molecular Targets in Protein Misfolding and Neurodegenerative Disease
A Book

by Pierfausto Seneci

  • Publisher : Academic Press
  • Release : 2014-10-07
  • Pages : 314
  • ISBN : 0128004991
  • Language : En, Es, Fr & De
GET BOOK

Aimed at "drug discoverers" – i.e. any scientist who is interested in neurodegenerative diseases in general, and in finding disease-modifying treatments in particular – the first edition of Molecular Targets in Protein Misfolding and Neurodegenerative Disease will contain both a detailed, discipline-specific coverage (paragraphs on medicinal chemistry, on clinical and preclinical characterization of compounds in development, on target identification and validation, on genetic factors influencing a pathology, etc.) and a drug discovery-oriented, overall evaluation of each target (validation, druggability, existing leads, etc.). Together these will satisfy the needs of various audiences, including in vitro biologists, pharmacologists, medicinal chemists, etc. Written to provide a comprehensive coverage of disease-modifying mechanisms and compounds against neurodegenerative diseases Provides a “drug discovery application oriented perspective, evaluating targets and candidates for their overall therapeutic potential Provides discipline-specific chapters (medicinal chemistry, target validation, preclinical and clinical development Provides an overview on a number of molecular mechanisms (e.g. phosphorylation, chaperon refolding, ubiquitination, autophagy, microtubule transportation, protease cleavage, etc.) with relevance for any disease area Contains a more thorough description of the therapeutic relevance of ~10 specific molecular targets

Chemical Modulators of Protein Misfolding and Neurodegenerative Disease

Chemical Modulators of Protein Misfolding and Neurodegenerative Disease
A Book

by Pierfausto Seneci

  • Publisher : Academic Press
  • Release : 2015-01-12
  • Pages : 260
  • ISBN : 9780128019443
  • Language : En, Es, Fr & De
GET BOOK

This book is a neurochemistry-based companion for Protein Misfolding and Neurodegenerative Diseases: Molecular Targets, an Elsevier title by the same author publishing in December 2014. While the first book focuses on biology and molecular targets, this companion book describes how these targets are regulated by small molecules and disease-modifying compounds. The book begins with a brief introduction to how key proteins become dysfunctional, and each subsequent chapter describes major disease mechanisms in Alzheimer's and other tauopathies. Properties and development status of these molecular targets and disease mechanisms are thoroughly described, as are small molecule effectors of autophagy and dis-aggregating agents. • Written to provide comprehensive coverage of neurodegenerative disease-modifying compounds; • Provides discipline-specific chapters that cover medicinal chemistry and clinical applications; • Provides an overview of more than 200 chemical classes and lead compounds, acting on selected molecular targets that are of relevance to any neurodegenerative disorder; • Coverage of misfolding diseases, chaperone proteins, ubiquitination and autophagy/oncology makes this book suitable for structural neurochemists, chemists, biologists, non-CNS scientists, and scientists interested in drug discovery.

Emerging Drugs and Targets for Alzheimer's Disease

Emerging Drugs and Targets for Alzheimer's Disease
Complete Set

by Ana Martinez

  • Publisher : Unknown Publisher
  • Release : 2010-05-07
  • Pages : 668
  • ISBN : 9781849730457
  • Language : En, Es, Fr & De
GET BOOK

A comprehensive 2-volume complete set that collects some of the most promising examples of new drugs currently under pharmaceutical development that will reach the Alzheimer's drug market over the next few years as disease-modifying therapeutics.

Environmental Factors in Neurodegenerative Diseases

Environmental Factors in Neurodegenerative Diseases
A Book

by Anonim

  • Publisher : Academic Press
  • Release : 2017-09-19
  • Pages : 290
  • ISBN : 0128127651
  • Language : En, Es, Fr & De
GET BOOK

Environmental Factors in Neurodegenerative Diseases, Volume One addresses contemporary advances in neurotoxicology, with thematic volumes providing authoritative review articles on key issues in the field. Updates in this new volume include chapters on Air pollution and neurodegenerative diseases, Mercury and Parkinson’s disease, Pesticides and PD: current evidence, Aluminum and neurodegeneration, Microglia and neurodegeneration, Dietary factors, Mitochondria in neurodegeneration, and Manganese and neurodegeneration. Edited by leading experts, volumes are designed as in-depth overviews of the latest topic developments that analyze the effect of varied chemical agents on the nervous system. It is an essential resource for researchers and graduate students alike. Includes, in one single publication, a selection of comprehensive reviews devoted to neurotoxicology Edited by high-profile, leading academics in the field, ensuring a quality publication for subscribers Aims to widen the scope for participation by international contributors, researchers and editorial board members outside North America Serves a broad audience of university faculty, researchers and students, as well as the industry, drug development companies and the government

Alzheimer's Disease - Modernizing Concept, Biological Diagnosis and Therapy

Alzheimer's Disease - Modernizing Concept, Biological Diagnosis and Therapy
A Book

by M.C. Carrillo,H. Hampel

  • Publisher : Karger Medical and Scientific Publishers
  • Release : 2012-04-23
  • Pages : 200
  • ISBN : 3805598033
  • Language : En, Es, Fr & De
GET BOOK

Expanding knowledge on genetic and epigenetic risk factors is rapidly enhancing our understanding of the complex molecular interactions and systems involved in the pathogenesis of Alzheimer’s disease. In this publication, leading experts discuss emerging novel conceptual models of the disease along with advances in the development of surrogate markers that will not only improve the accuracy of diagnostic technologies but also improve the prospects of developing disease-modifying interventions. The novel framework of the disease presented here highlights research on biological markers as well as efforts to validate technologies for early and accurate detection. It also introduces notion of a complex systems dysfunction that extends beyond prevailing ideas derived from the ‘amyloid’ or ‘tau’ hypotheses.This outstanding publication provides researchers, clinicians, students and other professionals interested in neurodegenerative disorders with a comprehensive update on current trends and future directions in therapy development, with special focus on advances in clinical trial designs.

Genotype - Proteotype - Phenotype Relationships in Neurodegenerative Diseases

Genotype - Proteotype - Phenotype Relationships in Neurodegenerative Diseases
A Book

by J. Cummings,J. Hardy,M. Poncet

  • Publisher : Springer Science & Business Media
  • Release : 2006-03-30
  • Pages : 166
  • ISBN : 3540265228
  • Language : En, Es, Fr & De
GET BOOK

Recent advances in understanding the role of protein dysmetabolism in neurodegeneration was the theme of the Fondation IPSEN meeting addressing Genotype-Proteotype-Phenotype relationships. Experts from international laboratories contributed to the current volume to produce a comprehensive overview of the role of protein misfolding in neurodegeneration. Links between genotype and protein characteristics and between proteotype and clinical phenomenology were discussed across diseases categories. Progress in understanding the role of abnormalities of protein metabolism may lead to the identification of biological markers relevant to disease monitoring and to the development of new therapeutic agents capable of modifying and ameliorating basic neurodegenerative mechanisms.

Role of Misfolded Proteins in the Pathogenesis of Neurodegenerative Disorders and Challenges impacting the development of Novel Therapies. An Overview.

Role of Misfolded Proteins in the Pathogenesis of Neurodegenerative Disorders and Challenges impacting the development of Novel Therapies. An Overview.
A Book

by Dr.Hakim Saboowala

  • Publisher : Dr.Hakim Saboowala
  • Release : 2020-11-09
  • Pages : 70
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Role of Misfolded Proteins in the Pathogenesis of Neurodegenerative Disorders and Challenges impacting the development of Novel Therapies. An Overview. A hallmark of neurodegenerative proteinopathies is the formation of misfolded protein aggregates that cause cellular toxicity and contribute to cellular proteostatic collapse. Therapeutic targeting of protein misfolding has generated unique challenges for drug discovery and development for several reasons, including: 1)The dynamic nature of the protein species involved, 2)Uncertainty about which forms of a given disease protein such as Monomers, Oligomers, or Insoluble aggregates, are primarily responsible for cellular toxicity, 3)Our still limited understanding about which components of the cellular proteo-static machinery these disease proteins interact with and 4) Lack of well-validated biomarkers for clinical trials. Therapeutic options are currently being explored that target different steps in the production and processing of proteins implicated in neurodegenerative disease, including synthesis, chaperone-assisted folding and trafficking, and degradation via the proteasome and autophagy pathways. Other therapies, like mTOR inhibitors and activators of the heat shock response, can rebalance the entire proteostatic network. Hence an attempt has been made in this E-Booklet to discuss major challenges that impact the development of novel therapies, including incomplete knowledge of druggable disease targets and their mechanism of action as well as a lack of biomarkers to monitor disease progression and therapeutic response. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)

The Propagation of Neurodegenerative Diseases by Inflammation and Exosomes

The Propagation of Neurodegenerative Diseases by Inflammation and Exosomes
A Book

by Valerie Sackmann

  • Publisher : Linköping University Electronic Press
  • Release : 2019-10-16
  • Pages : 60
  • ISBN : 9175190125
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative diseases with rates increasing along with the ageing global population. Despite best efforts, we still do not understand the etiopathogenesis of these diseases and there are no effective disease-modifying treatments. Cognitive deficiencies or motor complications that emerge during AD and PD are thought to be the result of the accumulation of misfolded, aggregate-prone proteins, such as amyloid-? (A?) and tau or ?-synuclein (?-syn), respectively. Growing evidence suggests that prefibrillar oligomers of A? and ?-syn (oA? and o?-syn) are key contributors to the progression of these diseases. The progressive accumulation of these proteins leads to a gradual spread of pathology throughout interconnected brain regions, but the mechanisms by which this spreading occurs are still largely unknown. Neuroinflammation has been recognised as an important contributor to neurodegenerative disease. It is hypothesised that a pro-inflammatory environment initiated by the innate immune system, either through activation from A? itself or indirectly through neuronal injury signals in AD. These phenomena are thought to either cause or accelerate AD, such that an anti-inflammatory approach may be neuroprotective. In paper I, we investigated whether different inflammatory environments affected the transfer of oA? between neuron-like cells, in addition to investigating inter- and intracellular protein changes. This study demonstrated that an anti-inflammatory environment reduces the transfer of oA? between cells. We also provide evidence that these cells begin to take on the “phenotype” of the inflammatory milieu, while also demonstrating that the expression profile of endosomal/lysosomal and protein trafficking proteins is altered during these conditions. Small extracellular vesicles called exosomes, which are key players in cell to cell communication, have been proposed to play an influential role in spreading neurodegenerative proteins between cells. Exosomes are small membranous vesicles that are formed by the inward budding of multivesicular bodies (MVBs). These MVBs can then merge with the plasma membrane to be released into the extracellular environment as vesicles, which serve as vehicles for transferring proteins, lipids, and mRNAs between cells. The ESCRT-dependent pathway is the most understood mechanism underlying exosome biogenesis. However, exosomes can also be formed through ESCRT-independent pathways, including through the hydrolysis of sphingomyelin by neutral sphingomyelinase 2 (nSMase2), which produces ceramide. Paper II investigated whether exosomes formed through an ESCRT-independent pathway plays a significant role in the transfer of o?-syn between neuron-like cells. As oxidative stress is a common feature in PD brains, which in turn dysregulates nSMase2 activity, we also tested our model under hypoxic conditions. Inhibition of nSMase2 significantly reduced the transfer of o?-syn between cells but also resulted in decreased ?-syn aggregation. Hypoxia did not influence o?-syn transfer, however, it significantly dysregulated the sphingolipid composition, which may be important for ?-syn binding to exosomes and exosome communication. During AD and PD, there is a noted reduction in the effectiveness of autophagy, a process critical to cellular proteostasis. Recent studies have uncovered shared regulatory mechanisms of exosome biogenesis and autophagy, suggesting that they are closely linked. Previous findings have shown that inhibition of autophagy in AD mice mediates A? trafficking through altering the secretion of A? in MVBs. To further study this effect, we investigated the interplay between autophagy and exosome secretion using ATG7 knock-out x APPNL-F knock-in AD mice in paper III. These autophagy-deficient AD mice had a reduced extracellular A? plaque load, but increased intracellular A?, which was found to be assembled into higher-ordered assemblies. While exosomal secretion was dysregulated in these mice, the amount of A? packaged into the exosomes was unchanged. Lastly, one of the biggest challenges in developing effective treatments for AD is the lack of early diagnosis of living patients. As the connection between exosomes and the spread of neurodegenerative proteins is still relatively new, there remains a diagnostic potential to be explored with exosomes. Paper IV aimed to develop a new diagnostic assay to detect oA? in exosomes isolated from human cerebrospinal fluid. Although exosomal oA? was readily detected in some of these samples, the assay’s sensitivity requires additional optimisation before it can be further validated for the clinic. In summary, the studies presented in this thesis have furthered our understanding of how inflammation, autophagy, and exosomes contribute to the intercellular transmission of AD and PD associated proteins. We have shown that an anti-inflammatory approach may slow down the progression of AD through reducing the transfer of oA? between cells. We also provide novel findings relating to the biogenesis of exosomes, which in turn affected the ability of exosomes to transmit neurodegenerative proteins between cells, and their association with autophagic processes. Finally, we have investigated the feasibility of exosomes as an early AD diagnostic marker. This work has helped to elucidate some of the mechanisms underlying the progression of neurodegenerative diseases, which may be useful targets for the investigation of new therapeutic avenues.

Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases

Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases
A Book

by Neville Vassallo

  • Publisher : Springer
  • Release : 2015-06-19
  • Pages : 163
  • ISBN : 3319183656
  • Language : En, Es, Fr & De
GET BOOK

This edited volume concerns a group of devastating neurological disorders that share a common pathological mechanism, namely the aggregation and deposition of insoluble, proteinaceous lesions, termed ‘amyloid’. Examples of cerebral amyloid disorders include common neurodegenerative diseases like Alzheimer’s disease-related dementia and Parkinson’s disease, as well as other less prevalent conditions like Huntington’s disease, cerebral amyloid angiopathy and the transmissible prion disorders. A disease-modifying therapeutic agent is still lacking for all these diseases, and there are no approved therapies that target amyloid formation directly. Nevertheless, a large and complex group of natural aromatic compounds known as polyphenols are rapidly emerging as potentially potent anti-amyloidogenic agents. This book collectively presents a considerable body of experimental and epidemiological evidence from peer-reviewed scientific publications that support a role for natural compounds and herbal extracts in the chemoprevention and therapy of amyloidogenic disorders. Each contribution is written by scientific experts in the relevant field; chapters are devoted to Mediterranean diet and olive oil phenols, traditional Chinese medicine, herbal extracts, polyphenols (with a particular emphasis on epigallocatechin-3-gallate) and bi-flavonoids, amongst others. The topic of this book is relevant to a wide audience, from academia and university students in the biological and chemical sciences, to physicians and allied health professionals, as well as people working in the nutraceutical industry.

Molecular Chaperones and Protein Folding As Therapeutic Targets in Parkinson's Disease and Other Synucleinopathies

Molecular Chaperones and Protein Folding As Therapeutic Targets in Parkinson's Disease and Other Synucleinopathies
A Book

by Applied Research Applied Research Press

  • Publisher : CreateSpace
  • Release : 2015-08-09
  • Pages : 44
  • ISBN : 9781516822478
  • Language : En, Es, Fr & De
GET BOOK

Changes in protein metabolism are key to disease onset and progression in many neurodegenerative diseases. As a prime example, in Parkinson's disease, folding, post-translational modification and recycling of the synaptic protein alpha-synuclein are clearly altered, leading to a progressive accumulation of pathogenic protein species and the formation of intracellular inclusion bodies. Altered protein folding is one of the first steps of an increasingly understood cascade in which alpha-synuclein forms complex oligomers and finally distinct protein aggregates, termed Lewy bodies and Lewy neurites. In neurons, an elaborated network of chaperone and co-chaperone proteins is instrumental in mediating protein folding and re-folding. In addition to their direct influence on client proteins, chaperones interact with protein degradation pathways such as the ubiquitin-proteasome-system or autophagy in order to ensure the effective removal of irreversibly misfolded and potentially pathogenic proteins. Because of the vital role of proper protein folding for protein homeostasis, a growing number of studies have evaluated the contribution of chaperone proteins to neurodegeneration. We herein review our current understanding of the involvement of chaperones, co-chaperones and chaperone-mediated autophagy in synucleinopathies with a focus on the Hsp90 and Hsp70 chaperone system. We discuss genetic and pathological studies in Parkinson's disease as well as experimental studies in models of synucleinopathies that explore molecular chaperones and protein degradation pathways as a novel therapeutic target. To this end, we examine the capacity of chaperones to prevent or modulate neurodegeneration and summarize the current progress in models of Parkinson's disease and related neurodegenerative disorders.

Environmental Factors in Neurodevelopmental and Neurodegenerative Disorders

Environmental Factors in Neurodevelopmental and Neurodegenerative Disorders
A Book

by Michael Aschner,Lucio G. Costa

  • Publisher : Academic Press
  • Release : 2015-06-18
  • Pages : 450
  • ISBN : 012800407X
  • Language : En, Es, Fr & De
GET BOOK

Environmental Factors in Neurodevelopmental and Neurodegenerative Disorders presents a state-of-the-art review of the effects of environmental contaminants on the development and degeneration of the human nervous system, brought together by world-leading experts in the field. Part One describes the adverse effects that the environment can have on neurological development, and how these effects may exhibit. Specific contaminants and their possible consequences of exposure are addressed (lead, methylmercury, alcohol), as well as specific disorders and the environmental factors associated with them, such as the effect of diet on attention deficit and hyperactivity disorders. Part Two tackles neurodegenerative disorders, specifically addressing their potential neurotoxic origins, and discussing the increasing interest in the effects that early exposure may have in later life. Environmental Factors in Neurodevelopmental and Neurodegenerative Disorders is an invaluable reference for those professionals working in the fields of toxicology, environmental health and neuroscience. Provides, for the first time, the cutting-edge theory of environmental impacts on both neurodegenerative and neurodevelopmental disorders Written by an international selection of the world’s foremost experts in the field of neurotoxicology Full-colour throughout, providing accurate and illustrative examples of neurotoxic effects in action An invaluable reference for those professionals working in the fields of toxicology, environmental health, and neuroscience

Emerging Drugs and Targets for Multiple Sclerosis

Emerging Drugs and Targets for Multiple Sclerosis
A Book

by Ana Martinez

  • Publisher : Royal Society of Chemistry
  • Release : 2019-06-28
  • Pages : 333
  • ISBN : 1788014502
  • Language : En, Es, Fr & De
GET BOOK

Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials. Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.

Emerging Drugs and Targets for Alzheimer's Disease

Emerging Drugs and Targets for Alzheimer's Disease
Volume 2: Neuronal Plasticity

by Ana Martinez

  • Publisher : Royal Society of Chemistry
  • Release : 2010-05-07
  • Pages : 242
  • ISBN : 1849731071
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective therapeutic intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts these books are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the drugs for neurodegeneration field.

Drug Design and Discovery in Alzheimer’s Disease

Drug Design and Discovery in Alzheimer’s Disease
A Book

by Atta-ur-Rahman,Muhammad Iqbal Choudhary

  • Publisher : Elsevier
  • Release : 2015-06-27
  • Pages : 784
  • ISBN : 0128039604
  • Language : En, Es, Fr & De
GET BOOK

Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Emerging Drugs and Targets for Alzheimer's Disease

Emerging Drugs and Targets for Alzheimer's Disease
Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism

by Ana Martinez

  • Publisher : Royal Society of Chemistry
  • Release : 2010-05-07
  • Pages : 287
  • ISBN : 1849731063
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism is an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

Alzheimer's Disease

Alzheimer's Disease
Targets for New Clinical Diagnostic and Therapeutic Strategies

by Renee D. Wegrzyn,Alan S. Rudolph

  • Publisher : CRC Press
  • Release : 2012-04-26
  • Pages : 298
  • ISBN : 1439827087
  • Language : En, Es, Fr & De
GET BOOK

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. With contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores: The basis of AD and the role of Aβ oligomers in development of disease Existing and emerging in vitro biomarker-based methodologies for the diagnosis of AD, focusing on genetic, biochemical, and conformational strategies In vivo imaging diagnostic approaches Evolving diagnostic criteria, health regulatory guidelines, biomarkers in clinical trials, and available and emerging therapies Recent progress in small-molecule disease-modifier drug discovery efforts for AD, specifically in the areas of Aβ, tau, and emerging neuroprotective/neurorepair approaches How a case study of AD raises issues regarding clinical and pathologic criteria, risk factors, and the amyloid hypothesis The molecular conformational factors that govern the pathogenicity of aggregating proteins, and how these factors could represent new targets for disease-modifying therapies The latest epidemiological, pathological, biochemical, and behavioral studies that may shed some light on the risk of developing AD and similar dementias after traumatic brain injury Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.

Animal Models for Neurodegenerative Disease

Animal Models for Neurodegenerative Disease
A Book

by Jesus Avila,Jose J Lucas,Felix Hernandez

  • Publisher : Royal Society of Chemistry
  • Release : 2011-05-30
  • Pages : 306
  • ISBN : 1849732752
  • Language : En, Es, Fr & De
GET BOOK

In recent years, medical developments have resulted in an increase in human life expectancy. Some developed countries now have a larger population of individuals aged over 64 than those under 14. One consequence of the ageing population is a higher incidence of certain neurodegenerative disorders. In order to prevent these, we need to learn more about them. This book provides up-to-date information on the use of transgenic mouse models in the study of neurodegenerative disorders such as Alzheimer's and Huntington's disease. By reproducing some of the pathological aspects of the diseases, these studies could reveal the mechanism for their onset or development. Some of the transgenic mice can also be used as targets for testing new compounds with the potential to prevent or combat these disorders. The editors have extensive knowledge and experience in this field and the book is aimed at undergraduates, postgraduates and academics. The chapters cover disorders including: Alzheimer's disease, Parkinson's disease, Huntington's and other CAG diseases, amyotrophic lateral sclerosis (ALS), recessive ataxias, disease caused by prions, and ischemia.

Vessel Based Imaging Techniques

Vessel Based Imaging Techniques
Diagnosis, Treatment, and Prevention

by Chun Yuan,Thomas S. Hatsukami,Mahmud Mossa-Basha

  • Publisher : Springer Nature
  • Release : 2019-10-10
  • Pages : 356
  • ISBN : 3030252493
  • Language : En, Es, Fr & De
GET BOOK

This book provides comprehensive information on new and existing vessel imaging techniques, with the intention of improving diagnosis, treatment, and prevention of vascular and related diseases. In recent years, vessel wall imaging has expanded greatly into other beds (such as the intracranial and peripheral arteries) and many of the techniques available for evaluation and diagnosis have only previously been published in research papers. This book bridges that gap for clinicians, applying cutting edge research to their everyday practice. The first six sections of the book are centered around individual vessel beds. These chapters will teach clinicians the multi-modality imaging techniques available to image these vessels and related pathology with a focus on new imaging tools and techniques. The final two sections of the book will offer a more comprehensive technical background aimed at imaging scientists for the imaging techniques used and the relationship of blood flow and modeling to disease monitoring and prevention. This is an ideal guide for radiologists and imaging scientists looking to learn the latest techniques in vessel imaging.